The policy explicitly lists a set of administrative and screening uses that are considered not medically necessary. These include testing required as a condition of employment or pre-employment, testing for participation in school or community athletics or extracurricular programs, court-ordered drug screening for medico-legal purposes (unless required by state regulation), screening of asymptomatic patients except where specifically allowed, testing as part of routine physicals or other administrative examinations (e.g., licensing, insurance), same-day multi-source screening across specimen types, blanket orders or routine standing orders for all patients, and specimen validity/adulteration testing. The policy also lists performing presumptive point-of-care testing followed by ordering duplicate presumptive immunoassay testing from a reference laboratory, and using immunoassay (IA) methods to "confirm" CLIA-waived presumptive results, as not medically necessary.

Presumptive testing criteria have been moved to a separate policy (CP.MP.208); this policy focuses on definitive (confirmatory/quantitative) testing. The document emphasizes that presumptive (immunoassay) testing is generally expected before definitive testing except when no reliable presumptive test exists (for example, synthetic cannabinoids). In addition, screening of asymptomatic patients is restricted and is considered not medically necessary unless specific covered indications in this policy apply.

The policy names several explicit not medically necessary situations: outpatient definitive testing that includes >14 drugs/drug classes is considered not medically necessary; numerous administrative and screening uses (employment, school athletics, court-ordered screening except as required by law, routine physicals, blanket orders, reflex definitive tests following POC presumptive testing, and specimen validity/adulteration testing) are also listed as not medically necessary. Coding tables identify specific CPT/HCPCS procedures that do not support coverage for these uses (see coding section), including HCPCS codes G0482 and G0483, which describe multi-class definitive panels of 15–21 and 22+ drug classes respectively, and large-panel CPT codes such as 0054U, 0082U, and 0328U.

For exact billing and coding details, refer to the policy's coding module. The policy lists numerous CPT codes that support coverage criteria (see CPT tables) and identifies HCPCS codes used for definitive drug testing. Pay particular attention to HCPCS descriptors and newer CPT entries when submitting claims. When billing, ensure the selected CPT/HCPCS code matches the number of drug classes and the method claimed (definitive LC/MS or GC/MS versus presumptive immunoassay); coding mismatches with the policy's coverage rules (for example, billing codes describing >14 drug classes) may result in denials.

Summary of scenarios not covered: outpatient definitive testing that includes more than 14 drug/drug classes is not covered. Testing performed for administrative purposes — such as employment or pre-employment screens, school or athletic program requirements, court-ordered or other medico-legal screening (unless state-mandated), routine physicals, licensing/insurance administrative exams, blanket orders, and routine standing orders for all patients — is not covered. Reflex definitive testing ordered solely because a point-of-care presumptive test was performed without a documented clinical indication is not covered, and use of immunoassay methods to 'confirm' CLIA‑waived presumptive test results is also listed as not medically necessary.

Coding-specific not-covered notes: HCPCS codes G0482 (definitive testing for 15–21 drug classes) and G0483 (22 or more drug classes) are identified in the policy as not supporting coverage criteria for outpatient definitive testing. The policy also lists specific CPT codes that do not support coverage (examples include large-panel CPT entries such as 0054U, 0082U, and 0328U); consult the coding tables in this policy for the full and current list.

Urine drug testing is commonly used to monitor adherence to controlled substance regimens and to detect misuse. Initial screening typically uses rapid immunoassays (point-of-care tests) because they are fast and practical, but these can produce false positives or negatives. Definitive confirmatory testing uses methods such as GC/MS or LC/MS/MS (often reported as LC-MS/MS) which provide specific identification and/or quantification of drugs and metabolites with higher analytic specificity and are appropriate when results will directly impact major clinical decisions or when presumptive tests are unreliable or inconsistent with the clinical presentation.